Rapport Therapeutics (NASDAQ:RAPP) Stock Price Up 11%

Posted by KOP Source Staff on Jul 23rd, 2024

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) shares traded up 11% during trading on Tuesday . The company traded as high as $22.87 and last traded at $22.72. 51,085 shares traded hands during trading, a decline of 76% from the average session volume of 215,976 shares. The stock had previously closed at $20.47.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. TD Cowen began coverage on Rapport Therapeutics in a research note on Tuesday, July 2nd. They issued a “buy” rating on the stock. Jefferies Financial Group initiated coverage on Rapport Therapeutics in a report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price on the stock. Finally, Stifel Nicolaus started coverage on Rapport Therapeutics in a research report on Tuesday, July 2nd. They set a “buy” rating and a $35.00 target price for the company.

Check Out Our Latest Research Report on RAPP

Rapport Therapeutics Trading Down 0.6 %

Insider Buying and Selling

In other Rapport Therapeutics news, Director James Healy bought 44,032 shares of the firm’s stock in a transaction on Monday, July 1st. The stock was purchased at an average cost of $24.52 per share, with a total value of $1,079,664.64. Following the completion of the purchase, the director now owns 40,851 shares in the company, valued at $1,001,666.52. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Rapport Therapeutics Company Profile

(Get Free Report)

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.